{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=8",
    "query": {
      "condition": "Gastrointestinal Carcinoma",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 2726,
    "total_pages": 273,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T19:30:02.517Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02834780",
      "title": "Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Hepatocellular Carcinoma",
        "Hepatocellular Carcinoma",
        "Liver Cancer",
        "Liver Neoplasms",
        "Hepatic Cancer",
        "Hepatic Carcinoma"
      ],
      "interventions": [
        {
          "name": "H3B-6527",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H3 Biomedicine Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2016-12-28",
      "completion_date": "2022-02-23",
      "has_results": true,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-10-13T19:30:02.517Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Newport Beach, California • Orange, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834780"
    },
    {
      "nct_id": "NCT03490669",
      "title": "Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Pancreatic Cancer",
        "Non Small Cell Lung Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "MSC-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2018-05-21",
      "completion_date": "2019-09-23",
      "has_results": false,
      "last_update_posted_date": "2024-04-05",
      "last_synced_at": "2026-10-13T19:30:02.517Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Grand Rapids, Michigan • Middletown, New Jersey + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03490669"
    },
    {
      "nct_id": "NCT06710223",
      "title": "Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "SD-101",
          "type": "DRUG"
        },
        {
          "name": "Cryotherapy",
          "type": "DEVICE"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2025-01-03",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-13T19:30:02.517Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06710223"
    },
    {
      "nct_id": "NCT02687230",
      "title": "Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Carcinoma",
        "Tumors That Express CA19-9"
      ],
      "interventions": [
        {
          "name": "MVT-2163",
          "type": "DRUG"
        },
        {
          "name": "MVT-5873",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioNTech Research & Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2016-07-11",
      "completion_date": "2017-05-05",
      "has_results": false,
      "last_update_posted_date": "2021-08-31",
      "last_synced_at": "2026-10-13T19:30:02.517Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02687230"
    },
    {
      "nct_id": "NCT05954871",
      "title": "Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "GDC-1971",
          "type": "DRUG"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2024-01-08",
      "completion_date": "2025-09-16",
      "has_results": false,
      "last_update_posted_date": "2025-11-13",
      "last_synced_at": "2026-10-13T19:30:02.517Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • San Antonio, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05954871"
    },
    {
      "nct_id": "NCT06050707",
      "title": "MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Radiotherapy - Low risk group",
          "type": "RADIATION"
        },
        {
          "name": "Radiotherapy - Standard risk group",
          "type": "RADIATION"
        },
        {
          "name": "Radiotherapy - Intermediate risk group",
          "type": "RADIATION"
        },
        {
          "name": "Radiotherapy - High risk group",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "University Health Network, Toronto",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2023-09-29",
      "completion_date": "2028-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-13T19:30:02.517Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06050707"
    },
    {
      "nct_id": "NCT01766219",
      "title": "CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Primary Cholangiocellular Carcinoma",
        "Advanced Adult Primary Liver Cancer",
        "Cholangiocarcinoma of the Extrahepatic Bile Duct",
        "Cholangiocarcinoma of the Gallbladder",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Metastatic Extrahepatic Bile Duct Cancer",
        "Recurrent Adult Primary Liver Cancer",
        "Recurrent Extrahepatic Bile Duct Cancer",
        "Unresectable Extrahepatic Bile Duct Cancer"
      ],
      "interventions": [
        {
          "name": "6,8-bis(benzylthio)octanoic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2013-05",
      "completion_date": "2018-05-18",
      "has_results": true,
      "last_update_posted_date": "2019-05-15",
      "last_synced_at": "2026-10-13T19:30:02.517Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01766219"
    },
    {
      "nct_id": "NCT04114136",
      "title": "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "NSCLC",
        "Hepatocellular Carcinoma",
        "Urothelial Cancer",
        "Gastric Adenocarcinoma",
        "HNSCC",
        "Esophageal Adenocarcinoma",
        "Microsatellite Instability-High Solid Malignant Tumor"
      ],
      "interventions": [
        {
          "name": "Nivolumab or Pembrolizumab (dependent upon approved indication)",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dan Zandberg",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2020-09-14",
      "completion_date": "2032-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-10-13T19:30:02.517Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04114136"
    },
    {
      "nct_id": "NCT00127036",
      "title": "Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma",
        "Colon Cancer"
      ],
      "interventions": [
        {
          "name": "XELOX",
          "type": "DRUG"
        },
        {
          "name": "XELIRI",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2003-10",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2017-03-23",
      "last_synced_at": "2026-10-13T19:30:02.517Z",
      "location_count": 12,
      "location_summary": "Deerfield Beach, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 8 more",
      "locations": [
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Port Charlotte",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00127036"
    },
    {
      "nct_id": "NCT06294548",
      "title": "A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Valemetostat",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2025-07-29",
      "completion_date": "2028-08-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-13T19:30:02.517Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06294548"
    }
  ]
}